Multiscale Modeling Tools for Structural Biology

$913,684P41FY2009RRNIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 27791341 Paper 27480508 Paper 27415450 Paper 26375252 Paper 25697908 Paper 25584862 Paper 25311861 Paper 25002512 Paper 24823618 Paper 24813122 Paper 24606137 Paper 24446720 Paper 24361582 Paper 24341684 Paper 24003028 Paper 23738772 Paper 23506287 Paper 23458553 Paper 23420416 Paper 23408879 Paper 23300421 Paper 23185650 Paper 22958641 Paper 22844233 Paper 22530969 Paper 22409201 Paper 22325284 Paper 22308333 Paper 22198475 Paper 22085022 Paper 22039358 Paper 22009676 Paper 21959236 Paper 21937512 Paper 21835981 Paper 21641297 Paper 21635128 Paper 21497083 Paper 21375305 Paper 20936808 Paper 20860388 Paper 20544962 Paper 20544957 Paper 20455589 Paper 20409463 Paper 20226790 Paper 20209096 Paper 20145801 Paper 20088755 Paper 20080513 Paper 20004163 Paper 19475704 Paper 19461661 Paper 19439655 Paper 19369428 Paper 19367856 Paper 19323547 Paper 19199626 Paper 19049302 Paper 19012437 Paper 18981051 Paper 18940610 Paper 18662776 Paper 18644380 Paper 18643097 Paper 18572416 Paper 18550813 Paper 18491385 Paper 18487310 Paper 18462966 Paper 18412341 Paper 18412139 Paper 18408157 Paper 18391430 Paper 18386898 Paper 18304802 Paper 18183310 Paper 18178653 Paper 18172838 Paper 18000050 Paper 17942695 Paper 17932932 Paper 17880128 Paper 17683199 Paper 17407093 Paper 17373704 Paper 17368485 Paper 17342701 Paper 17297998 Paper 17288425 Paper 17085501 Paper 17079293 Paper 16943448 Paper 16900491 Paper 16689630 Paper 16536547 Paper 16487974 Paper 16422651 Paper 16381893 Paper 16292303

Abstract

Abstract The objectives of this project are first, to increase the efficacy and safety of live poxvirus vaccines against smallpox and other virulent poxviruses, and second, to increase the efficacy of live vaccinia virus vaccines as a vaccine platform for protection against multiple agents important in the fields of biodefense and emerging infections. The specific aims of this project are as follows: 1. To identify key mechanisms of viral induction of immune responses, particularly those contributing to the efficacy of vaccinia virus MVA vaccines: The goal is to learn how to maximize the induction of protective responses through the manipulation of viral control of these processes. 2. To determine if different orthopoxviruses, specifically vaccinia virus MVA, vaccinia virus (WR), and cowpox virus differentially affect dendritic cell (DC) responses to viral infection. The goal is to determine the mechanisms contributing to species-specific effects upon DC functions. We will use this information to manipulate viral control of DC responses to infection in order to maximize protective responses induced by vaccine viruses. 3. To determine if the efficacies of MVA vaccines can be improved by modification of accessory proteins encoded by the vaccine virus. The goal is to determine if the stability, delivery regimen, and the efficacy of vaccinia virus MVA vaccines can be improved by the expression of two cowpox/vaccinia virus accessory genes that encode proteins enabling the MVA virus vaccine to embed its intracellular mature virus (IMV) within A-type inclusion particles. The current MVA virus vaccine provides a safe alternative to the currently licensed smallpox vaccines that are associated with a significant degree of adverse effects. However, because of the MVA virus is defective for replication in human cells, large doses of MVA are needed, and multiple doses may be needed for effective protection against specific agents. Therefore, methods to enhance the stability and delivery of this vaccine, as well as methods to enhance the immunogenicity of this vaccine virus, preferably to the point of reducing the vaccination to a single dose, would significantly enhance the efficacy of this vaccine vector.

View original record on NIH RePORTER →